Essential Drugs Monitor No. 031 (2002)
(2002; 72 pages) [French] [Spanish]

Table of Contents

	Essential Drugs Monitor
	Editorial
		Promoting science or sales?
	Conflict of Interest
		Editors act on clinical trial reporting
		More journal editors voice their concerns
		Maintaining the integrity of the clinical evidence base
		USA: growing reaction to drug representatives' visits?
		Study shows links between industry and clinical guide writers
	Letter from the Editor
	News Desk
		Calls for stronger consumer voice at conference on medicines and media
		Regulating drug promotion in Europe: meeting debates way forward
		Alliance protects rights to genetic resources
		Russia acts to curb counterfeits
		ISDB defines genuinely innovative drugs
		Delhi: commitment to continuing pharmacy education
		Drug companies employ many more staff for marketing than R&D
		World Consumer Rights Day
		US groups criticise magazine's special issue on health
		Australia reports on a decade of quality use
		Adverse reactions to drugs increase
		Learning how to get RUD messages across to communities
		UN initiative evaluates HIV medicines
		Conference promotes regional collaboration in SAARC countries
		Tackling antimicrobial resistance
		Study on research and development costs questioned
		WHO at work in Afghanistan
	Netscan, Meetings & Courses
	Research
		Analysing drug advertisements in Russia
		Canadian survey on direct-to-consumer advertising
		Research update
	Drug Promotion
		Women and drug promotion: "the essence of womanhood is now in tablet form¹"
		Europe: call to leave current advertising regulations intact
		New report on French sales representatives' visits
		FDA reviews its direct-to-consumer advertising policy
		An innovative approach to educating medical students about pharmaceutical promotion
		New WHO/NGO database on drug promotion launched
		Direct-to-consumer prescription drug advertising: is there evidence of health benefits?
		The Australian Pharmaceutical Manufacturers Association Code of Conduct: guiding the promotion of prescription medicines
		India: campaign to tackle unethical promotion
		Doctors and drug companies: analysing a complex relationship
	National Drug Policy
		How to develop national drug policies New WHO guidelines
		Brazil boosts information on generics
		How to implement national drug policies successfully
	Access
		Neglected diseases: MSF's exhibition takes to the road
		USA: problems of access to drugs
	Rational Use
		Developing clinical practice guidelines? Australia updates methodology
		Germany: action on overprescribing
		China's first problem-based pharmacotherapy teaching workshop
		US study shows cost-cutting potential of generics
	Access
		Conference calls for action on neglected diseases
		WHO fact sheet on drug price information services
		The Medicines Crossing Borders Project - improving the quality of donations
		Germany's new drug donation declaration
		Conference explores intellectual property issues post-Doha

Essential Drugs Monitor No. 031 (2002)

WORLD HEALTH ORGANIZATION